גלוואן ישראל - עברית - Ministry of Health

גלוואן

teva pharmaceutical industries ltd, israel - nonoxinol 9; ricinoleic acid - פתילות - nonoxinol 9 140 mg; ricinoleic acid 25 mg - intravaginal contraceptives - spermicide for the control of conception.

רייאטאז 200 מג ישראל - עברית - Ministry of Health

רייאטאז 200 מג

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

רייאטאז 300 מג ישראל - עברית - Ministry of Health

רייאטאז 300 מג

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

אינרביק ישראל - עברית - Ministry of Health

אינרביק

bristol, myers squibb (israel) limited, israel - fedratinib as dihydrochloride monohydrate - קפסולות - fedratinib as dihydrochloride monohydrate 100 mg - fedratinib

רייאטאז 150 מ"ג ישראל - עברית - Ministry of Health

רייאטאז 150 מ"ג

bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

ברקלוד 0.5 מג ישראל - עברית - Ministry of Health

ברקלוד 0.5 מג

bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ברקלוד 1 מ"ג ישראל - עברית - Ministry of Health

ברקלוד 1 מ"ג

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

יירבוי 5 מגמל ישראל - עברית - Ministry of Health

יירבוי 5 מגמל

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

ספרייסל 100 מג ישראל - עברית - Ministry of Health

ספרייסל 100 מג

bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

אורנסיה 250 מג ישראל - עברית - Ministry of Health

אורנסיה 250 מג

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.